Lensar, Inc. reported a narrower loss for the fourth quarter of 2025, posting a net loss of $1.5M as the medical device maker saw mixed results in its laser cataract surgery business. The company recorded a loss per share of $0.12, compared to a loss of $1.61 in the year-ago period, representing a 92.5% improvement.
Revenue totaled $16.0M for the quarter, down 4.2% from $16.7M in Q4 2024. The decline in total revenue came despite strong procedure volume momentum, with the company reporting worldwide procedure volume growth of 20.0% for the quarter. Lensar’s installed base reached 200 total ALLY systems at quarter end as the company continues to expand its footprint in the ophthalmology market.
The revenue composition showed diverging trends across business lines. Procedure Revenue led the company’s performance with $9.4M in revenue, climbing 23.6% year-over-year as surgeons increasingly utilized Lensar’s laser systems for cataract procedures. The commercial-stage company focuses on designing and marketing laser systems for cataract treatment and related surgical applications.
Wall Street maintains a cautious stance on the stock, with analyst consensus standing at 0 buy, 4 hold, and 1 sell ratings. The company operates in the competitive medical device sector where laser-assisted cataract surgery continues to gain adoption among ophthalmologists seeking precision surgical outcomes.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.